^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
11/15/2017
Excerpt:
Ontruzant in combination with capecitabine or 5‑fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
Secondary therapy:
capecitabine; cisplatin + 5-fluorouracil